Katherine Bowdish

Going after the machinery, not just the mutation

Katherine Bowdish runs a company built on a contrarian premise. Most cancer drugs chase the genetic mutations that turn healthy cells malignant. Bowdish, as President and CEO of PIC Therapeutics, is going one step upstream - after the machinery a tumor uses to turn those mutated instructions into the proteins that keep it alive.

PIC Therapeutics is a small biotech in Natick, Massachusetts, developing small-molecule drugs that modulate RNA translation. The company's lead program targets eIF4E, a translation-initiation factor that Bowdish and her colleagues describe as a kind of master switch for cancer signaling. Flip it off selectively, the thinking goes, and you can starve a tumor of the oncogene proteins driving it while sparing normal cells. The first target is drug-resistant metastatic breast cancer, one of the harder problems in oncology because the disease keeps finding ways around existing treatments.

It is a bet that fits the pattern of Bowdish's career: find the science almost everyone else is walking past, then build a company around it. She has done it more than once, and the companies she started early now sit in the histories of larger firms.

A founder who keeps starting over

Bowdish's scientific roots are in antibody discovery. She founded Prolifaron, an innovator in antibody technologies that grew through partnerships with large pharmaceutical companies and was ultimately acquired by Alexion Pharmaceuticals. She went on to serve as President of Alexion Antibody Technologies and Senior Vice President of antibody discovery at Alexion.

Rather than settle into a single corporate seat, she kept returning to the blank page. She co-founded and led Anaphore as President and CEO, a platform company pioneering Atrimers, a class of trivalent protein pharmaceuticals. In 2012 she was named President and Chief Scientific Officer of Permeon Biologics, a company working on getting biologic drugs inside cells - a notoriously difficult delivery problem.

From the funder's chair back to the founder's

In 2013 Bowdish joined Sanofi, where her vantage point shifted. She became Vice President and Head of R&D Strategy and launched Sanofi Sunrise, a venture investment and partnering vehicle designed to accelerate early-stage pioneering science and move it toward patients. For a serial founder, it was a role on the other side of the table - deciding which young companies and ideas were worth backing.

She did not stay there. In August 2020 she was appointed President, CEO and Director of PIC Therapeutics, stepping back into the seat she seems to prefer: running a small team chasing a first-in-mechanism idea. It is a move that says something about how she reads risk. Having spent years evaluating pioneering science as an investor, she chose to go run one of the boldest versions of it herself.

The $35 million test

In October 2022, PIC Therapeutics closed a $35 million Series A financing led by the healthcare investment firm OrbiMed, with participation from Lumira Ventures, the Harrington Discovery Institute and existing backers including Advent Life Sciences. The money was earmarked to push the company's lead eIF4E modulator toward first-in-human, first-in-mechanism clinical studies in advanced metastatic breast cancer, and to broaden the pipeline into other cancers.

For a company of roughly seven people, it was a substantial vote of confidence in an unconventional approach. Bowdish framed the raise as validation of the science rather than a finish line.

Why translation, and why now

The scientific logic behind PIC is worth sitting with, because it explains why Bowdish chose this fight. Cancer is usually described as a disease of the genome - the wrong genes, switched on. But a mutated gene still has to be read and translated into protein before it can do damage. That translation step, controlled by a molecular assembly called the Pre-Initiation Complex, is where PIC gets its name and its target.

By modulating translation rather than blocking a single mutated protein, the approach aims to address two of oncology's most stubborn problems at once: the heterogeneity of tumors, where no two cancer cells look quite alike, and resistance, where tumors adapt around a drug. The company's stated goal is to selectively reshape the cancer cell's proteome to trigger cell death while leaving healthy cells largely untouched.

Whether it works is a question the clinic will answer. But the choice of target is characteristic. Bowdish has built a career on backing science that is early, difficult and unproven, and then doing the unglamorous work of turning it into a company that can test the idea for real.